MTS105 for advanced liver cancer with GPC3
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment called MTS105 for people with advanced liver cancer (HCC) that has not responded to standard therapies. It targets a protein called GPC3 found on some liver cancer cells, aiming to stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of liver cancer called hepatocellular carcinoma (HCC), confirmed by a biopsy, and your tumor has a specific protein called GPC3.
- You have tried at least one immunotherapy (like a checkpoint inhibitor) and one targeted therapy (like a TKI or anti-VEGF drug), and those treatments are no longer working or caused bad side effects.
- Your liver is still working fairly well (Child-Pugh score A) and your overall health is good enough to be up and about (ECOG score 0 or 1).
- You have not had any major treatments for your cancer in the last few weeks, and any side effects from previous treatments are mild or gone.
- You do not have active infections, severe heart problems, or other cancers that are not cured.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cells that are designed to find and attack liver cancer cells with a specific marker (GPC3). If you have advanced hepatocellular carcinoma (liver cancer) that has not responded to standard treatments, this study may be an option to explore.
This trial tests a new type of immune cell therapy called Metabolically Armed GPC3 CAR-T cells (Meta10-GPC3) for people with liver cancer that has come back or spread and cannot be removed by surgery. The cells are designed to target a protein called GPC3 on cancer cells and may help shrink tumors.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
Hear when a new Liver Cancer, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.